Lumos Has Built the Flu-Season Funnel; It Still Won't Put a Number On It

Lumos Diagnostics is a roughly $42 million medical-device microcap selling a single CLIA-waived test, FebriDx, into U.S. urgent care. For six months its story has had exactly three moving parts: build awareness, get sites to evaluate, get them live before the flu season. On 26 October the company delivered its best funnel numbers yet — and then, as it has every quarter since listing this narrative, declined to say what any of it is worth in dollars.

The funnel is real. It is also small.

The quarter's hard facts: 50 new live accounts added in roughly four weeks, taking live sites to 265 across 29 states, while sites in active evaluation rose by 80 to 485. Thirteen of the 100 largest accounts — the ones management calls the whale strategy — are now live or evaluating. WellStreet, the flagship multi-site chain, sits at 44 sites live with the target of expanding to all remaining locations by flu season still described as intact.

What has genuinely changed is the conversion machinery. Paul Kase, who runs sales, put the evaluation-to-standardised-adoption lag at 60 to 90-plus days, gated less by clinical belief than by claims data coming back from payers — the economic validation that makes a test stick. He also claimed more than half of onboarded accounts now run a standing workflow rather than hit-and-miss shelf stock: “So each account is a little different, but I'd say it's over 50%.” — Paul Kase, Head of Marketing and Sales · 2026-10-26 That is the single most important sentence in the call, and it is unquantified beyond a yes/no.

Against that, the CEO's own caveat about how this will read quarter to quarter: “it will be very, very lumpy... we're kind of in that law of small numbers here.” — Douglas Ward, Managing Director and CEO · 2026-10-26 A 400-location non-profit health system or a 65,000-caregiver Midwest network can move the reported number by double digits simply by deciding when to standardise. That cuts both ways.

A revenue line still smaller than the marketing budget

Q1 product revenue was $564,000, most of it FebriDx. On a like-for-like basis — excluding last July's one-off PHASE exclusivity fee — product revenue rose 224% and FebriDx specifically 351%. Services revenue of $1.5 million was down about $500,000, driven by less work booked against the Hologic IP contract, for which a new proposal is outstanding. Cash went from $15.4 million to $11.8 million, absorbing a $1 million inventory build ahead of the season, sales and marketing spend, the pediatric study and fit-out of the new Carlsbad facility, partly offset by Ryder Capital exercising 26.1 million options at $0.07.

The structural point, repeated by CFO Barrie Lambert: this is a seasonal business where Q1 and Q2 are quiet and the revenue arrives January through April. The capital raise that funded the launch is what buys the company through that gap. Asked directly whether there is enough cash to get through the season, Doug Ward answered with a flat yes — conditional on selling product.

The refusal is now the most repeated line in the story

Here is the tension. Ward opened by saying the business is tracking exactly to plan and that he is "very, very bullish." Then came the guidance question, and the same answer investors have heard for three quarters.

We just don't provide guidance, guys, at this stage in the company... at most other companies that I've been at, whether it's the Roches of the world and others, they don't even budget for that brand-new product in that first year.

That is nearly verbatim from March: “we don't give guidance around our revenue and certainly around the volume” — Douglas Ward, Chief Executive Officer · 2026-03-02 — and from April: “We don't provide guidance around the revenue numbers and our volume numbers at this stage.” — Douglas Ward, Chief Executive Officer and Managing Director · 2026-04-21 Test volumes are withheld as commercially sensitive under the PHASE agreement; distributor inventory is invisible to shareholders. Chair Sam Lanyon's framing is that the leading indicators simply are not mature: “I still think it's a little bit ahead of where we are today.” — Samuel Lanyon, Chair · 2026-10-26 That echoes his own April admission that “in a distributor network, sometimes you lose fidelity of data” — Samuel Lanyon, Chairman · 2026-04-21 — which is a fair thing to say once, and a harder thing to say for a third consecutive quarter while describing commercialisation as ahead of schedule.

The number that moved the wrong way

Buried after the marketing slides was the quarter's genuine news, and it was not good. The BARDA-funded pediatric study has roughly 400 patients enrolled against a 700-to-800 target for the calendar year. Three paediatric emergency departments have been added to supplement slow primary-care recruitment, and management has approached the FDA with BARDA to reset scope and timing, with a meeting due at year-end.

We are at about roughly 400 patients enrolled... The performance of the test is excellent... Right now, it's just a volume gain for us.

Ward is right that enrolment is not an efficacy signal — but the silence is telling. In April the pediatric trial was described as one that would "definitely go into the end of the calendar year" without any disclosure of a shortfall against internal targets. This is the first quarter where the gap is on the record, and it lands just as milestone payments and the next BARDA tranche depend on it. Enrollment pace is not a Lumos-specific problem; it is the shared risk of every small-cap clinical story in this market, visible across the small biotech complex in themes like pace of enrollment and the ubiquity of open label extension language as companies stretch timelines to keep trials alive.

Reading the keyword map, and the absence of a tape

What Lumos now talks about most is, unsurprisingly, the season itself: flu season sits at the top of the company's keyword profile this quarter with respiratory season close behind — a shift from prior quarters when the conversation was dominated by the CLIA waiver and the mechanics of reimbursement. The new vocabulary is operational: Urgent Care conferences, LinkedIn campaigns, account-based marketing, and a foothold in Primary Care, where a 12-site, 300-provider Northeast group has already been trained. The Ohio State Health System television segment — and the anecdote of patients walking in asking to use FebriDx — is the kind of consumer pull that no marketing budget buys.

The honest limitation on this dossier: Lumos has no price tape and no fundamentals block in our data. There is no drawdown, no breakout, no valuation multiple to weigh against the rhetoric — only a $42 million market cap, a transcript, and a company asking investors to underwrite one flu season on leading indicators it will not quantify. Repeat orders are described as visible but "a little early"; WellStreet's remaining sites are "still intact" as a target but with no visibility on timing; the Carlsbad facility is on track for year-end validation.

So the trade here is not a re-rating story yet. It is a binary on execution inside a four-month window: does the funnel convert to revenue at a rate that justifies the $11.8 million of remaining cash, and does the pediatric study get rescued at the FDA meeting before BARDA patience runs out? Ward's closing line — that everything is going "exactly according to the plan" — will be settled by the March quarterly, not by another deck of click-through rates.